

Noemi Lois

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8457565/publications.pdf>

Version: 2024-02-01

72
papers

3,450
citations

279487

23
h-index

155451

55
g-index

74
all docs

74
docs citations

74
times ranked

3832
citing authors

#	ARTICLE	IF	CITATIONS
1	The progress in understanding and treatment of diabetic retinopathy. Progress in Retinal and Eye Research, 2016, 51, 156-186.	7.3	730
2	Phenotypic Subtypes of Stargardt Macular Dystrophyâ€“Fundus Flavimaculatus. JAMA Ophthalmology, 2001, 119, 359.	2.6	278
3	Internal Limiting Membrane Peeling versus No Peeling for Idiopathic Full-Thickness Macular Hole: A Pragmatic Randomized Controlled Trial. , 2011, 52, 1586.		220
4	Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss11Commercial interests: None.. American Journal of Ophthalmology, 2002, 133, 341-349.	1.7	179
5	Pseudophakic retinal detachment. Survey of Ophthalmology, 2003, 48, 467-487.	1.7	173
6	Fundus autofluorescence in stargardt macular dystrophyâ€“fundus flavimaculatus. American Journal of Ophthalmology, 2004, 138, 55-63.	1.7	167
7	Vitreotomy with Internal Limiting Membrane Peeling versus No Peeling for Idiopathic Full-Thickness Macular Hole. Ophthalmology, 2014, 121, 649-655.	2.5	149
8	A Longitudinal Study of Stargardt Disease: Clinical and Electrophysiologic Assessment, Progression, and Genotype Correlations. American Journal of Ophthalmology, 2013, 155, 1075-1088.e13.	1.7	121
9	Internal Limiting Membrane Peeling in Vitreo-retinal Surgery. Survey of Ophthalmology, 2008, 53, 368-396.	1.7	94
10	Environmental tobacco smoke exposure and eye disease. British Journal of Ophthalmology, 2008, 92, 1304-1310.	2.1	85
11	Progression of Retinal Pigment Epithelial Atrophy in Stargardt Disease. American Journal of Ophthalmology, 2012, 154, 146-154.	1.7	82
12	RETINAL PIGMENT EPITHELIAL ATROPHY IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIâ€“VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2013, 33, 13-22.	1.0	76
13	GEOGRAPHIC ATROPHY IN RETINAL ANGIOMATOUS PROLIFERATION. Retina, 2011, 31, 1043-1052.	1.0	73
14	Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. Survey of Ophthalmology, 2018, 63, 816-850.	1.7	73
15	Endothelial Progenitor Cells in Diabetic Retinopathy. Frontiers in Endocrinology, 2014, 5, 44.	1.5	67
16	Intrafamilial variation of phenotype in Stargardt macular dystrophy-Fundus flavimaculatus. Investigative Ophthalmology and Visual Science, 1999, 40, 2668-75.	3.3	58
17	Optical Coherence Tomography for the Monitoring of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 399-406.	2.5	55
18	Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-248.	1.3	53

#	ARTICLE	IF	CITATIONS
19	A New Model of Posterior Capsule Opacification in Rodents. , 2003, 44, 3450.		51
20	Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review. Health Technology Assessment, 2018, 22, 1-168.	1.3	43
21	Targeting QKI-7 in vivo restores endothelial cell function in diabetes. Nature Communications, 2020, 11, 3812.	5.8	39
22	Different lasers and techniques for proliferative diabetic retinopathy. The Cochrane Library, 2018, 2018, CD012314.	1.5	32
23	Posterior Capsule Opacification in Mice. JAMA Ophthalmology, 2005, 123, 71.	2.6	28
24	Animal Models of Retinal Vein Occlusion. , 2017, 58, 6175.		28
25	FIRST FAILED MACULAR HOLE SURGERY OR REOPENING OF A PREVIOUSLY CLOSED HOLE. Retina, 2020, 40, 1-15.	1.0	28
26	Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis. BMJ Open, 2014, 4, e005292-e005292.	0.8	26
27	Enhanced Function of Induced Pluripotent Stem Cell-Derived Endothelial Cells Through ESM1 Signaling. Stem Cells, 2019, 37, 226-239.	1.4	25
28	Effect of TGF- β 2 and Anti-TGF- β 2 Antibody in a New In Vivo Rodent Model of Posterior Capsule Opacification. , 2005, 46, 4260.		24
29	Cost-effectiveness of internal limiting membrane peeling versus no peeling for patients with an idiopathic full-thickness macular hole: results from a randomised controlled trial. British Journal of Ophthalmology, 2012, 96, 438-443.	2.1	24
30	STAT3 activation in circulating myeloid-derived cells contributes to retinal microvascular dysfunction in diabetes. Journal of Neuroinflammation, 2019, 16, 138.	3.1	22
31	Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial. Trials, 2019, 20, 122.	0.7	22
32	Electric currents and lens regeneration in the rat. Experimental Eye Research, 2010, 90, 316-323.	1.2	21
33	Treatments for macular oedema following central retinal vein occlusion: systematic review. BMJ Open, 2014, 4, e004120.	0.8	21
34	Electrical stimulation of retinal pigment epithelial cells. Experimental Eye Research, 2010, 91, 195-204.	1.2	20
35	Fundus autofluorescence in patients with retinal pigment epithelial (RPE) tears: an in-vivo evaluation of RPE resurfacing. Graefes' Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1059-1063.	1.0	19
36	The Epidemiology of Stargardt Disease in the United Kingdom. Ophthalmology Retina, 2017, 1, 508-513.	1.2	19

#	ARTICLE	IF	CITATIONS
37	Circulating Leukocyte Alterations and the Development/Progression of Diabetic Retinopathy in Type 1 Diabetic Patients - A Pilot Study. <i>Current Eye Research</i> , 2020, 45, 1144-1154.	0.7	19
38	Erythropoietin in diabetic retinopathy. <i>Vision Research</i> , 2017, 139, 237-242.	0.7	18
39	Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2014, 18, 1-254.	1.3	17
40	Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy. <i>Ophthalmology</i> , 2021, 128, 561-573.	2.5	15
41	Fenofibrate for Diabetic Retinopathy. <i>Asia-Pacific Journal of Ophthalmology</i> , 2019, 7, 422-426.	1.3	14
42	Clinical and cost-effectiveness of internal limiting membrane peeling for patients with idiopathic full thickness macular hole. Protocol for a Randomised Controlled Trial: FILMS (Full-thickness macular) Tj ETQq0 0 0 rgBT.7Overload 10 Tf 50	1.7	10
43	Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 1411-1418.	1.0	11
44	Diabetic retinopathy and the use of laser photocoagulation: is it cost-effective to treat early?. <i>BMJ Open Ophthalmology</i> , 2017, 2, e000021.	0.8	10
45	Effect of short-term macrophage depletion in the development of posterior capsule opacification in rodents. <i>British Journal of Ophthalmology</i> , 2008, 92, 1528-1533.	2.1	9
46	Polarized retinal pigment epithelium generates electrical signals that diminish with age and regulate retinal pathology. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5552-5564.	1.6	9
47	Endothelial Cells Derived From Patients With Diabetic Macular Edema Recapitulate Clinical Evaluations of Anti-VEGF Responsiveness Through the Neuronal Pentraxin 2 Pathway. <i>Diabetes</i> , 2020, 69, 2170-2185.	0.3	9
48	Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial. <i>Trials</i> , 2022, 23, 99.	0.7	8
49	Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vessels in Diabetic retinopathy (EMERALD). <i>BMJ Open</i> , 2019, 9, e027795.	0.8	7
50	A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. <i>Journal of Clinical Medicine</i> , 2020, 9, 2225.	1.0	7
51	Risk factors associated with progression to referable retinopathy: a type 2 diabetes mellitus cohort study in the Republic of Ireland. <i>Diabetic Medicine</i> , 2020, 37, 1000-1007.	1.2	7
52	Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration. <i>The Cochrane Library</i> , 2020, 12, CD013154.	1.5	7
53	Instrumental variable methods for a binary outcome were used to informatively address noncompliance in a randomized trial in surgery. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 126-132.	2.4	6
54	PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA. <i>Retina</i> , 2020, 40, 919-927.	1.0	5

#	ARTICLE	IF	CITATIONS
55	Fenofibrate for diabetic retinopathy. The Cochrane Library, 0, , .	1.5	4
56	The importance of the epithelial fibre cell interface to lens regeneration in an in vivo rat model and in a human bag-in-the-lens (BiL) sample. Experimental Eye Research, 2021, 213, 108808.	1.2	4
57	IMPACT OF RETINAL ISCHEMIA ON FUNCTIONAL AND ANATOMICAL OUTCOMES AFTER ANTI-ANGIOGENIC VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN PATIENTS WITH RETINAL VEIN OCCLUSION. Retina, 2020, 40, 1098-1109.	1.0	3
58	Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort. British Journal of Ophthalmology, 2021, , bjophthalmol-2020-318570.	2.1	3
59	Anatomic and Functional Correlates in Lesions of Retinal Vein Occlusion. , 2021, 62, 10.		3
60	Reporting of Complications in Retinal Detachment Surgical Trials. JAMA Ophthalmology, 2021, 139, 898.	1.4	3
61	Treatment for diabetic macular oedema: looking further into the evidence. Annals of Eye Science, 2018, 3, 2-2.	1.1	1
62	Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration. The Cochrane Library, 2018, , .	1.5	1
63	Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. The Cochrane Library, 2020, , .	1.5	1
64	Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study. Health Technology Assessment, 2021, 25, 1-104.	1.3	1
65	Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study. British Journal of Ophthalmology, 2021, , bjophthalmol-2021-318816.	2.1	1
66	Progression of Electroretinogram Responses in Stargardt's Fundus Flavimaculatus: A longitudinal study. Acta Ophthalmologica, 2011, 89, 0-0.	0.6	1
67	Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy. Eye, 2022, , .	1.1	1
68	Reply. Retina, 2013, 33, 1998-1999.	1.0	0
69	Reply to Correspondence by Calugaru and Calugaru to the Article Entitled "Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion" by Khayat et al.. Survey of Ophthalmology, 2019, 64, 593-594.	1.7	0
70	Reply. Retina, 2020, 40, e48-e49.	1.0	0
71	Reply. Ophthalmology, 2021, 128, e46-e47.	2.5	0
72	Predictive factors associated with anatomical and functional outcomes following panretinal photocoagulation in people with proliferative diabetic retinopathy. Retina, 2022, Publish Ahead of Print, .	1.0	0